SOMERSET, NJ--(May 1, 2017) - MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of mHealth and cloud-based clinical and practice management solutions, today announced that it has successfully developed Health Information Exchange (HIE) interfaces for interoperability between its highly ranked clinical platforms and leading hospitals including Torrance Memorial Medical Center and NYU Langone Medical Center.

The recent HIE interfaces expand the reach of MTBC's platform by affording MTBC's clients the flexibility of seamlessly exchanging clinical information between MTBC's clinical platform and popular third-party EHR systems. Furthermore, the interfaces will result in elimination of unnecessary paperwork; increased patient engagement; reduced clinical errors; and effective public health reporting and monitoring. The new HIE interoperability between the systems will provide caregivers with clinical decision support tools for more effective care and treatment, resulting in improved healthcare quality.

New clients expected to generate more than $1 million in annual revenues

 

SOMERSET, NJ--(Apr 27, 2017) - MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of mHealth and cloud-based clinical and practice management solutions, announced the signing of two new clients yesterday who are expected to generate more than $1 million in combined, recurring, annual revenues, starting in third quarter 2017, marking a record day of new business signings for MTBC.

 

"We're very pleased to welcome these new clients, who are regional leaders in their respective specialties of pain management and orthopedics," said Karl Johnson, MTBC SVP, Sales and Marketing. He continued, "Yesterday was a record day of closings for us and we'll continue expanding our reach into new markets as we enable healthcare providers to optimize revenues, while reducing operating costs."

Purchase price of US$6.72 per share, or approximately US$85 million in aggregate

Acquisition to strengthen Zoetis’ pipeline in companion animal therapeutics for chronic pain, a global area estimated at US$400 million annually1

 

PARSIPPANY, N.J. & TULLAMORE, Ireland -- Zoetis Inc. (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced an agreement in which Zoetis, through a wholly owned subsidiary (“Zoetis Bidco”), will purchase Nexvet, an innovator in monoclonal antibody therapies for companion animals, for a purchase price of US$6.72 per share, representing an aggregate equity valuation of approximately US$85 million. The acquisition will strengthen Zoetis’ pipeline of solutions for chronic pain management in dogs and cats, which represents an area of high-need in companion animal health.

NEWPORT BEACH, Calif. --  Alliance HealthCare Services, Inc. (NASDAQ: AIQ) (the “Company,” “Alliance,” “we” or “our”), a leading national provider of outsourced radiology, oncology and interventional services, announced today that it has signed a definitive merger agreement with Tahoe Investment Group Co., Ltd. (“Tahoe”), formerly known as Fujian Thai Hot Investment Co., Ltd., THAIHOT Investment Company Limited (“THAIHOT”), THAIHOT Investment Company US Limited and Alliance HealthCare Services Merger Sub Limited (each an indirect wholly owned subsidiary of Tahoe, and, together with Tahoe, the “Tahoe Group”), pursuant to which the Tahoe Group will acquire all of the outstanding common stock of Alliance that is not beneficially owned by the Tahoe Group or owned by Alliance as treasury stock, for US $13.25 per share in cash, or a total payment of approximately US $75 million to equity holders of Alliance other than the Tahoe Group.